<p>A new cash lifeline from United Therapeutics buys the diabetes drugmaker more time to increase sales of its inhaled insulin. Also, make-or-break news is fast approaching for cardiovascular drugmaker, Amarin. MNKD, UTHR, AMRN</p>

A new cash lifeline from United Therapeutics buys the diabetes drugmaker more time to increase sales of its inhaled insulin. Also, make-or-break news is fast approaching for cardiovascular drugmaker, Amarin. MNKD, UTHR, AMRN

<p>A new cash&nbsp;lifeline from United Therapeutics buys the diabetes drugmaker more time to increase sales of its inhaled&nbsp;insulin. Also, make-or-break news is fast approaching for cardiovascular drugmaker, Amarin. MNKD, UTHR, AMRN</p>

Healthcare: MannKind's Back from the Brink

Healthcare, technology, energy, consumer goods, and more. Every day, Motley Fool analysts break down a specific industry and the stocks making headlines. Questions? Comments? Email us at IndustryFocus@fool.com.

Share Healthcare: MannKind's Back from the Brink

Sign up to save your podcasts

Healthcare: MannKind's Back from the Brink

Healthcare: MannKind's Back from the Brink